Amneal Pharmaceuticals (AMRX) Q2 2024 earnings summary

Executive summary

• Q2 2024 net revenue rose 17% year-over-year to $702M, with broad-based growth across Generics, Specialty, AvKARE, and international segments.

• Adjusted EBITDA increased 11% to $162M, while GAAP net income was $6M, down from $12M in Q2 2023 due to higher costs and opioid litigation charges.

• CREXONT® (IPX203) received FDA approval for Parkinson's disease, with U.S. launch planned for September and expected peak sales of $300M–$500M.

• Full-year 2024 guidance was raised for revenue, adjusted EBITDA, and operating cash flow, reflecting double-digit growth expectations.

• Net leverage improved to 4.4x, with continued deleveraging and focus on reducing debt.

Financial highlights

• Q2 2024 net revenue: $702M (+17.1% YoY); adjusted EBITDA: $162M (+11% YoY); adjusted diluted EPS: $0.16 (down from $0.19 in Q2 2023); GAAP net income: $6M (down from $12M in Q2 2023).

• H1 2024 net revenue: $1.36B (+17.7% YoY); adjusted EBITDA: $315M (+19.9% YoY); adjusted diluted EPS: $0.30 (down from $0.31 in H1 2023).

• Q2 2024 gross margin: 35.6% (GAAP), adjusted gross margin: 41%; Q2 2024 operating income: $95.5M (+19.2% YoY).

• Cash and cash equivalents at June 30, 2024: $44M; total debt: $2.4B.

• Net cash from operations for H1 2024: $35.2M (down from $128.4M in H1 2023); operating cash flow for H1 2024: $122M (up from $10M in H1 2023).

Outlook and guidance

• 2024 net revenue guidance raised to $2.70–$2.80B (13%–17% growth); adjusted EBITDA guidance increased to $610M–$630M (9%–13% growth).

• Adjusted diluted EPS guidance for 2024: $0.57–$0.63.

• Operating cash flow guidance raised to $280M–$320M; CapEx expected at $60M–$70M.

• Net leverage targeted to fall to ~4x by year-end and below 3x over the next few years.

• CREXONT® (IPX203) U.S. launch expected in September 2024.